Discover AMPK Modulators with the Transcreener ADP2 Assay
The Transcreener ADP² Kinase Assay directly measures the ADP produced by AMPK (also known as AMP-Activated Protein Kinase or 5' Adenosine Monophosphate-Activated Protein Kinase). By measuring the production of ADP researchers can effectively determine the activity of the AMPK enzyme. The assay provides a powerful tool to screen compound libraries for AMPK modulators to help find new therapeutics for a variety of different diseases including coronavirus, autoimmune diseases, and cancer.
The Role of AMPK As Therapeutic Target
AMPK is a drug target in many areas, including metabolism, inflammatory diseases, tumor suppression, and more recently, the coronavirus. SARS-CoV-2 uses the ACE2 receptor to infect the human body. Research has shown that AMPK can increase the expression and stability of ACE2. Once the coronavirus is in the body, it leads to a downregulation of ACE2. This causes a chain of events leading to deadly cardio-pulmonary issues. One drug currently on the market Metformin, activates AMPK via phosphorylation. Currently used as a Diabetes drug, Metformin has positive effects on both lipid and glucose metabolism via AMPK. Another AMPK activator AICAR has shown to improve alveolar and capillary barriers preventing damage from an infection like SARS-CoV-2 in mice. Further work needs to be done but AMPK is a target of interest for coronavirus treatment.
Direct Detection of ADP to Measure AMPK Enzymatic Activity
The workhorse. Used in many large screens. Best deck and signal stability.
Positive FI signal. Compatible with simple fluorescence plate readers. Faster read time than FP or TR-FRET.
For customers who prefer TR-FRET detection. Uses the same filter set as HTRF®.
Learn why direct ADP detection is the best HTS assay method for Kinases and ATPases